265 related articles for article (PubMed ID: 23418512)
1. Dysfunctional activation of neurotensin/IL-8 pathway in hepatocellular carcinoma is associated with increased inflammatory response in microenvironment, more epithelial mesenchymal transition in cancer and worse prognosis in patients.
Yu J; Ren X; Chen Y; Liu P; Wei X; Li H; Ying G; Chen K; Winkler H; Hao X
PLoS One; 2013; 8(2):e56069. PubMed ID: 23418512
[TBL] [Abstract][Full Text] [Related]
2. NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma.
Ye Y; Long X; Zhang L; Chen J; Liu P; Li H; Wei F; Yu W; Ren X; Yu J
Oncotarget; 2016 Oct; 7(43):70303-70322. PubMed ID: 27611941
[TBL] [Abstract][Full Text] [Related]
3. Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Xiao P; Long X; Zhang L; Ye Y; Guo J; Liu P; Zhang R; Ning J; Yu W; Wei F; Yu J
Oncoimmunology; 2018; 7(7):e1440166. PubMed ID: 29900041
[TBL] [Abstract][Full Text] [Related]
4. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway.
Fu XT; Dai Z; Song K; Zhang ZJ; Zhou ZJ; Zhou SL; Zhao YM; Xiao YS; Sun QM; Ding ZB; Fan J
Int J Oncol; 2015 Feb; 46(2):587-96. PubMed ID: 25405790
[TBL] [Abstract][Full Text] [Related]
5. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment.
Zhang J; Zhang Q; Lou Y; Fu Q; Chen Q; Wei T; Yang J; Tang J; Wang J; Chen Y; Zhang X; Zhang J; Bai X; Liang T
Hepatology; 2018 May; 67(5):1872-1889. PubMed ID: 29171040
[TBL] [Abstract][Full Text] [Related]
7. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
8. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
Jin Y; Wang J; Han J; Luo D; Sun Z
Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
[TBL] [Abstract][Full Text] [Related]
9. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
10. Acidic Microenvironment Up-Regulates Exosomal miR-21 and miR-10b in Early-Stage Hepatocellular Carcinoma to Promote Cancer Cell Proliferation and Metastasis.
Tian XP; Wang CY; Jin XH; Li M; Wang FW; Huang WJ; Yun JP; Xu RH; Cai QQ; Xie D
Theranostics; 2019; 9(7):1965-1979. PubMed ID: 31037150
[No Abstract] [Full Text] [Related]
11. IL-37b suppresses epithelial mesenchymal transition in hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling.
Pu XY; Zheng DF; Shen A; Gu HT; Wei XF; Mou T; Zhang JB; Liu R
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):408-415. PubMed ID: 30201411
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic models for identifying the risk of hepatocellular carcinoma based on epithelial-mesenchymal transition-associated genes.
Xiong C; Wang G; Bai D
Bioengineered; 2020 Dec; 11(1):1034-1046. PubMed ID: 32951492
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of partial epithelial mesenchymal transition-related genes in hepatocellular carcinoma.
Lei Y; Yan W; Lin Z; Liu J; Tian D; Han P
J Cell Mol Med; 2021 Jan; 25(1):448-462. PubMed ID: 33215860
[TBL] [Abstract][Full Text] [Related]
14. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
[TBL] [Abstract][Full Text] [Related]
15. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.
Hou KZ; Fu ZQ; Gong H
World J Gastroenterol; 2015 Jan; 21(2):475-83. PubMed ID: 25593462
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of intratumour inflammatory cytokine mRNA levels of hepatocellular carcinoma patients and activation of two distinct pathways govern IL-8 induced epithelial-mesenchymal transition in human hepatic cancer cell lines.
Peng S; Chen Y; Gong Y; Li Z; Xie R; Lin Y; Zou B; Li J; Zeng L
Cytokine; 2019 Jul; 119():81-89. PubMed ID: 30903867
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma.
Liu Y; Jiang P; Wang G; Liu X; Luo S
Eur J Surg Oncol; 2018 Jul; 44(7):1087-1093. PubMed ID: 29764705
[TBL] [Abstract][Full Text] [Related]
18. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
[TBL] [Abstract][Full Text] [Related]
19. Proline-rich protein 11 silencing inhibits hepatocellular carcinoma growth and epithelial-mesenchymal transition through β-catenin signaling.
Qiao W; Wang H; Zhang X; Luo K
Gene; 2019 Jan; 681():7-14. PubMed ID: 30248355
[TBL] [Abstract][Full Text] [Related]
20. Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment.
Li Q; Ma L; Shen S; Guo Y; Cao Q; Cai X; Feng J; Yan Y; Hu T; Luo S; Zhou L; Peng B; Yang Z; Hua Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):303. PubMed ID: 31296243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
